Drug intelligence / Profile preview

TQB3015

Development stage: Discontinued
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

TQB3015 is an orally bioavailable small molecule inhibitor of Src homology region 2 domain-containing phosphatase 2 (SHP2), developed by Chia Tai-Tianqing Pharmaceutical Group. SHP2 is a non-receptor protein tyrosine phosphatase that plays a critical role in the RAS/MAPK signaling pathway, which is frequently dysregulated in various cancers. By inhibiting SHP2, TQB3015 aims to suppress tumor growth and overcome resistance to other targeted therapies, such as KRAS or EGFR inhibitors. It is currently being evaluated in Phase I clinical trials for the treatment of advanced malignant tumors.

Targets

PTPN11 (Tyrosine-protein phosphatase non-receptor type 11)

Beyond the preview

Go deeper on TQB3015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQB3015.

Explore the full profile